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To our knowledge， no standard chemotherapy for patients with hormone-refractory prostate 
cancer (HRPC) has been established. Since most patients with HRPC are elderly and have bone 
metastasis， cytotoxic chemotherapy causes them to be at high risk for myelosuppression. Therefore， 
chemotherapeutic agents with low toxicity and good compliance should be elected. 
We conducted three regimens for HRPC on an outpatient basis. Eligibility criteria were defined 
as serial rising PSA values on 3 or more occasions at least 2 weeks apart or radiological new or extensive 
lesions under hormonal therapy. The first regimen is comprised of cyclophosphamide (CPM)， 100 
mg/day， UFT， 400 mg/day， and estramustine phosphate (EMP)， 560 mg/day in two daily fractions. 
The second regimen is comprised of an oral administration of dexamethasone (DEX) (0.5-2 mg/day). 
The third regimen is comprised of DEX， 1 mg/day， cyclophosphamide， 100 mg/day and UFT， 400 
mg/day in two daily fractions. Post-therapy prostate-specific antigen (PSA) level in serum， objective 
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response on bone scan or measurable disease， and symptomatic response on bone pain were assessed. 
All regimens showed clinical efficacy with mild toxicity. Indications and limitations ofthese regimens 
are discussed. 
Further， the combination trials of taxane and EMP in patients with HRPC are reviewed. 
(Acta Urol. Jpn. 48: 713-718， 2002) 





































る.具体的には， cyclophosphamide (以下 CPM)，
UFT (uracil， tegafur合剤)， estramustine phos-












a. CPM， UFT， EMP併用療法 (CUE療法)










c. DEX， CPM， UFT併用療法 (DCU療法)
















始直前値で割った値(%)を算出し， 50%以上， 50% 
未満，上昇の3群に分けて検討した.骨痛の評価は，
鎮痛剤の投与量の変化によって，消失/改善(鎮痛剤
西村，ほか:再燃性前立腺癌 化学療法 715 
Table 1. Patients' characteristics 
CPM， UFT， EMP DEX DEX， CPM， UFT 
26例 37例 44例
開始時年齢(中央値)歳 50-82 (67) 53-89 (74) 50-84 (69) 
初診から再燃までの期間(中央値)月 6-74 (19) 3-48 (23) 4-128 (33) 
治療前 PSA(中央値)ng/ml 3.6-2，240 (33) 2.4-3，570 (38) 4.6-2，530 (33) 
骨痛の有無
有 17例 18例 16例
鉦 9例 19例 281YU 
再燃時の病巣(重複有)
骨 23例 32例 39例
リンパ節 5例 6例 9伊J
前立腺 3例 5 f7U 5例
PSAのみ 2例 5例 6例
Table 2. PSA response 
PSA下降率 CPM， UFT， E乱1P
症例2数61Fj(%) 
>=50% 16 (62) 
く50% 6 (23) 





























DEX DEX， CPM， UFT 
症例3数7例(%) 症例4数4例(%) 
23 (62) 28 (64) 
9 (24) 10 (23) 




























例が CUE併用療法)を受け， 3例が DEX単独療法
を受けていた.血清 PSAによる評価の結果を Table
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Table 3. Symptomatic response and objective response 




骨痛 17 18 16 
消失/改善 5 (29) 1 (61) 9 (56) 
不変 10 (59) 5 (28) 6 (38) 
増悪 2 (12) 2 (11) 1 (6) 
他党所見
骨シンチグラム 16 21 30 
改善 1 (6) 4 (19) 10 (3) 
不変 9 (56) 8 (38) 10 (33) 
増悪 6 (38) 9 (43) 10 (33) 
2方向測定可能病変 3 5 7 
完全/部分寛解 2 (6) 1 (20) 1 (14) 
不変 o ( 0) 2 (40) 3 (43) 
増悪 1 (3) 2 (40) 3 (43) 
Table 4. Side effects 
CPM， UFT， EMP 
症例2数6例(%) 
血液系
白血球減少 I (42) 
貧血 10 (38) 
血小板減少 3 (12) 
消化器系
食欲低下 13 (50) 
肝機能障害 1 (4) 
その他
倦怠感 7 (27) 
血尿 7 (27) 












た.リンパ節は 7例中 l例のみ PRが得られた.骨




































を始めた7) 実際， EMP単剤後の再燃7例中 5例に
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Table 5. Estramustine plus taxane regimen 
PSA CR+PR in 恥1edian 恥fedian
著者 レジメン 症例数 decline measurable tlme to survival Tox-cGitSy ) (>= >=50% disease progresslOn tIme 
Estramustine(8rmn40 g/mdgam/ydh 4 a，Day Dla-y 7 l-7) 
SmithらB) EPatocpiomdE( 100) 40 65% 45% 4 months rnzths 白血球減少μtaxel (135 mg/mm"， Day 2) 
everγ3 weeks 
Savareseら9)DEHvsoyetcdrEavrtEoan3cxlowiesrletien(sk7oes0n(e TIlσg(4/m0gIT/I1kE1耳d/daDaya，ydD2a) ialy )l-5)4判6 68% 50% 8 months 20 ffi.~~ 24% months 倦感呼 24% 
ry :l weeKS 困難 22% 
PaditueI(60-l1mo0 ogm/mgzkl/-mgm/midna2キy) ) 血栓血糖症 25% 
Kellyら10) E …IU路胤凶山s討ti 56 67% 45% 6 months 19.9f高E 38% 
Cevaerbyop守latin ( months リン酸血症
weeks 42% 







血清 PSAの評価 (PSAdecline> =50%) ，画像上の




















る抗癌剤あるいは DEXによる治療を行ってきた. 3 
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